Entecavir-13C2,15N
CAT:
804-HY-13623S1
Size:
500 µg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Entecavir-13C2,15N
- UNSPSC Description: Entecavir-13C2,15N (BMS200475-13C2,15N; SQ34676-13C2,15N) is a 13C- and 15N-labeled Entecavir (HY-13623). Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.
- Target Antigen: HBV; Isotope-Labeled Compounds
- Type: Isotope-Labeled Compounds
- Related Pathways: Anti-infection;Others
- Applications: COVID-19-immunoregulation
- Field of Research: Infection
- Assay Protocol: https://www.medchemexpress.com/entecavir-13c2-15n.html
- Solubility: 10 mM in DMSO
- Smiles: O[C@H]([C@H]1CO)C[C@H](N2[13C]3=C([13C](NC(N)=N3)=O)[15N]=C2)C1=C
- Molecular Weight: 280.26
- References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.|[2]Innaimo SF, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997 Jul;41(7):1444-9.|[3]Rivkin A, et al. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin. 2005 Nov;21(11):1845-57.|[4]Genovesi EV, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother. 1998 Dec;42(12):3209-18.
- Shipping Conditions: Room temperature
- Storage Conditions: 4°C (Powder, stored under nitrogen)
- Clinical Information: No Development Reported